EUVIMEDΑνακαλύψτε το EUVIMED
Crossref

Atractylenolide III Mitigates Alzheimer's Disease by Enhancing Autophagy via the YY1 ‐ TFEB Pathway

Xiaowei Zhang, Shuang Chu, Yanli Huang iD, Zhonghua Li, Junying Song, Pan Wang, Yunfang Su, Zhenqiang Zhang iD, Zhishen Xie

Phytotherapy Research · 2025-10 · 39 (10) · 4474-4490

DOI: 10.1002/ptr.70069 ↗

At a glance

Journal article in Phytotherapy Research, published online on 2025-08-20. Written by Xiaowei Zhang and 8 co-authors. Institution: Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, China. Major MEDLINE topics: Alzheimer Disease, Autophagy, Sesquiterpenes, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors. Cited 7 times so far (Crossref); 74 references. Funded by: Special Research Project of Henan Province on Traditional Chinese Medicine, National Natural Science Foundation of China, Program for Science & Technology Innovation Talents in Universities of Henan Province.

ΠερίληψηSubjectsΒιβλιογραφικά στοιχείαCiteRelated studies

Abstract (original language)

Autophagy dysregulation serves as a significant pathogenic factor in Alzheimer's disease (AD), with transcription factor EB (TFEB) acting as a pivotal transcription factor that governs the process of autophagy. Atractylenolide III (AT‐III), a terpenoid compound found in medicinal Atractylodes macrocephala Koidz , is well‐known for its role in antioxidant and anti‐inflammatory activities. The purpose of this study is to explore the beneficial impact of AT‐III on AD pathology and identify the mechanisms involved. C. elegans CL4176, SH‐SY5Y APP SWE , and APP/PS1 mice were used to investigate the efficacy and possible mechanism of AT‐III on the treatment of AD. AT‐III reduced amyloid protein (Aβ) deposition in C. elegans CL4176 heads, prolonged the paralysis time, and reduced Aβ levels in SH‐SY5Y APP SWE cells. AT‐III improved the learning and memory ability of APP/PS1 mice and decreased the deposition of Aβ plaques. Transcriptomics and experimental validation showed that AT‐III stimulated transcription and translation of autolysosome‐associated genes. AT‐III enhanced co‐localization of LC3 and LAMP2 with Aβ in APP/PS1 mice. Meanwhile, AT‐III increased TFEB transcriptional activity, mRNA, and protein levels in the nucleus. Furthermore, AT‐III enhanced the expression of Yin Yang 1 (YY1) protein, an upstream regulator of TFEB, and led to the stimulation of autophagy and lysosome biogenesis both in vivo and in vitro. The observed effects were reversed upon silencing YY1. AT‐III may regulate the YY1‐TFEB pathway, thereby restoring autophagy flux disturbances and ameliorating AD‐related pathological changes and cognitive decline. This study provides a promising lead compound for intervention in AD.

Subjects

MeSH terms (MEDLINE)

Alzheimer DiseaseAutophagySesquiterpenesBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsYY1 Transcription FactorLactonesAnimalsHumansMiceCaenorhabditis elegansAmyloid beta-PeptidesSignal TransductionCell Line, TumorMice, TransgenicAtractylodesDisease Models, AnimalMale

Author keywords

C. elegansAlzheimer's diseaseAtractylenolide IIIamyloid‐βautophagycognitive impairment

Substances

SesquiterpenesBasic Helix-Loop-Helix Leucine Zipper Transcription Factorsatractylenolide IIIYY1 Transcription FactorLactonesAmyloid beta-PeptidesTFEB protein, human

Authors and institutions

  • Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, China.
  • Collaborative Innovation Center of Prevention and Treatment of Major Diseases by Chinese and Western Medicine, Henan Province, Henan University of Chinese Medicine, Zhengzhou, China.

ORCID profiles: Yanli Huang, Zhenqiang Zhang

Funding

  • Special Research Project of Henan Province on Traditional Chinese Medicine
  • National Natural Science Foundation of China
  • Program for Science & Technology Innovation Talents in Universities of Henan Province
  • Key Research and Development Program of Henan Province
  • Henan Provincial Science and Technology Research and Development Program Joint Fund

Cite

APA

Zhang, X., Chu, S., Huang, Y., Li, Z., Song, J., Wang, P., Su, Y., Zhang, Z., & Xie, Z. (2025). Atractylenolide III Mitigates Alzheimer's Disease by Enhancing Autophagy via the YY1 ‐ TFEB Pathway. Phytotherapy Research, 39(10), 4474-4490. https://doi.org/10.1002/ptr.70069

Vancouver

Zhang X, Chu S, Huang Y, Li Z, Song J, Wang P, et al. Atractylenolide III Mitigates Alzheimer's Disease by Enhancing Autophagy via the YY1 ‐ TFEB Pathway. Phytotherapy Research. 2025;39(10):4474-4490. doi:10.1002/ptr.70069

BibTeX
@article{Zhang2025,
  author = {Zhang, Xiaowei and Chu, Shuang and Huang, Yanli and Li, Zhonghua and Song, Junying and Wang, Pan and Su, Yunfang and Zhang, Zhenqiang and Xie, Zhishen},
  title = {Atractylenolide III Mitigates Alzheimer's Disease by Enhancing Autophagy via the YY1 ‐ TFEB Pathway},
  journal = {Phytotherapy Research},
  year = {2025},
  volume = {39},
  number = {10},
  pages = {4474--4490},
  doi = {10.1002/ptr.70069}
}
Start for free →